fda application - Robuta Search

https://www.talk.bio/2025/08/stealth-biotherapeutics-resubmits-third.html Stealth BioTherapeutics Resubmits Third FDA Application for Rare Disease Drug fda application rare disease stealth biotherapeutics third https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016-a-first-in-class-allogeneic-anti-egfr-cell-therapy-302052466.html Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a... Feb 4, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation... new drug application fda clearance https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831-in-igg4-related-disease-302306506.html Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in... Nov 15, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation... new drug application fda clearance https://www.drugpatentwatch.com/p/NDA/213953 Kyzatrex / testosterone undecanoate FDA New drug application 213953 global drug patent coverage,... Get details on NDA 213953 international drug patents, generic equivalents and API sources new drug application testosterone undecanoate global patent fda https://maestrodatabase.com/blog/takeda-and-protagonist-announce-us-fda-accepts-new-drug-application-and-grants-priority-review-for-rusfertide-as-a-potential-first-in-class-therapy-for-polycythemia-vera MAESTrO: Takeda and Protagonist announce US FDA accepts new drug application and grants priority... https://www.pharmatutor.org/pharma-news/2016/fda-cleare-%20sangamo-biosciences-ind-application-for-zfn-mediated-genome-editing-treatment-mps-i FDA cleared Sangamo BioSciences IND application For ZFN-Mediated genome editing treatment Of MPS I... Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's... https://www.biospace.com/spinogenix-announces-fda-clearance-of-ind-application-for-spg302-a-novel-therapy-for-the-treatment-of-als Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment... Jul 17, 2024 - Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients... https://www.prnewswire.com/news-releases/tr1x-announces-fda-clearance-of-first-investigational-new-drug-application-for-trx103-an-allogeneic-regulatory-t-cell-therapy-to-treat-autoimmune-diseases-302112587.html Tr1X Announces FDA Clearance of First Investigational New Drug Application for TRX103, an... Apr 10, 2024 - /PRNewswire/ -- Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel allogeneic regulatory T cell... new drug application https://www.complianceg.com/compliance-webinars/csa-revolution-season-two-episode-2-with-fda/ CSA Rev Season-2|FDA Talks on Data Integrity&CSA Application Jul 17, 2025 - In This Webinar, Learn about Data Integrity Challenges and Avoiding Compliance Issues and CSA Application to Data Integrity. data integrity csa rev season fda https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-ind-application-for-ace1831-an-anti-cd20-armed-allogeneic-gamma-delta-t-cell-therapy-candidate-to-treat-patients-with-non-hodgkins-lymphoma-301570711.html Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic... Jun 20, 2022 - /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC)... https://www.amgen.com/newsroom/press-releases/2008/03/amgen-to-discuss-romiplostim-application-at-fda-odac-meeting Amgen to Discuss Romiplostim Application at FDA ODAC Meeting| Amgen to discuss amgen application fda odac https://www.amgen.com/newsroom/press-releases/2021/05/amgen-announces-tezepelumab-biologics-license-application-submitted-to-u-s--fda Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA| Amgen license application submitted to amgen announces tezepelumab https://www.bioworld.com/articles/691009-fda-approves-orphan-drug-application-for-tlr-ad1-immunotherapy?v=preview FDA approves orphan drug application for TLR-AD1 immunotherapy | BioWorld Novaccess Global Inc. has announced the approval of its application with the FDA for orphan drug designation for TLR-AD1, a vaccine immunotherapy for the... orphan drug fda application tlr immunotherapy https://www.prnewswire.com/news-releases/fda-accepts-supplemental-new-drug-application-for-eisais-lenvatinib-for-the-treatment-of-liver-cancer-300526147.html FDA Accepts Supplemental New Drug Application for Eisai's Lenvatinib for the Treatment of Liver... /PRNewswire/ -- Eisai Inc. today announced the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for...